Pre-Conference Workshop Day

Tuesday, October 22

8:00 am Registration & Morning Coffee

Workshop A 9:00-12:00

Enhancing Potency Assays for TIL: Unlocking Precision & Reliability for Regulatory Approval


With the regulatory approval of Lifileucel and more candidates preparing for commercialization, gaining clarity on effective potency assays to streamline regulatory approval is now at the forefront.

Join this workshop to:

  • Explore how to select and establish potency assays to demonstrate product efficacy
  • Understand how to adapt potency assays to different stages of the clinical development in cell therapies
  • Gain clarity on regulatory requirements for next generation engineered TILs
  • Evaluate requirements of specific and non-specific potency assays when meeting regulatory standards
  • Gain insights into solutions in managing low viability tumor cell lines when developing assays for challenging indications

12:00 pm Lunch Break & Networking

Workshop B 1:00-4:00

Overcoming Neoantigen Screening Bottlenecks & Empowering Neoantigen Predictions for Expansion of Neoantigen Reactive TILs

  • Sergio Quezada Chief Scientific Officer, Achilles Therapeutics
  • James Yang Senior Investigator, Steven Rosenberg Group, National Institute of Health New!


Many TIL developers face bottlenecks in screening for neoantigens and predicting immunogenicity and selectivity potential of discovered neoantigens, which exasperates manufacturing timelines. This workshop discusses solutions and current advancements to expedite processes, crucial for advancing TIL therapy development amidst burgeoning demand.

Join this workshop to:

  • Discuss the challenge of intratumor heterogeneity and tools for targeting clonal neoantigens which are present on every tumour cell
  • Explore state-of-the-art bioinformatics tools to accelerate isolation of potentially immunogenic neoantigens
  • Evaluate tools to screen for challenging antigens such as MHC class 2 neoantigens
  • Dive deep into the development of assays for predicting the selectivity and immunogenicity of neoantigens, including assay design and validation methodologies
  • Engage in technical discussions on the challenges and limitations associated with current approaches in neoantigen screening and prediction
  • Consider the ability to overcome immune evasion mechanisms through neoantigen selection